Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

8.26

 

EUR

 

+0.73 %

5,420 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Compare
+0.73%
+1.72%
+4.56%
+23.28%
+119.68%
+254.51%
+72.8%
+530.95%
-98.64%

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
59.16M EUR
Turnover
98K EUR
P/E (adj.) (25e)
17.25
EV/EBIT (adj.) (25e)
18.41
P/B (25e)
10.97
EV/S (25e)
4
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
9.00 EUR
Updated
2025-03-04
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2025-03-04

Latest extensive report

Released: 2023-10-06

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/3
2025

General meeting '25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nexstim H2'24 preview: Profitable H2 in expectations
Analyst Comment by
Antti Siltanen

Nexstim H2'24 preview: Profitable H2 in expectations

Nexstim will publish its H2 report on Thursday, February 27 at 9 am EET. The second half of an eventful year full of surprises was marked in particular by the cooperation agreement with Brainlab and the import license for the Indian market.

Nexstim
Research by
Antti Siltanen

Nexstim: Good end to a strong year

Nexstim's strong 2024 culminated in a seasonally busy Q4 sales season. The total number of system sales reported for the year was 28, up from 24 last year and the best sales year in Nexstim's history.

Nexstim
Forum discussions
Nu analys på Nexstim utgavs i dag Nexstim: New year starts in a mixed atmosphere - Inderes
1/3/2024, 1:22 PM
by Pia Maljanen
2
Det här bolaget är mycket omtalat nu, åtminstone i Finland. Här är en ny analys av Nexstim. Nexstims aktiekurs har sjunkit kraftigt de senaste dagarna och därmed har risk/rewardförhållandet återigen blivit attraktivt. Vi höjer således vår rekommendation till Öka (tidigare Minska)...
3/4/2025, 11:16 PM
by börsen84
1
Nexstim publicerar sin H2-rapport den 27 februari. Den senare delen av året drevs av samarbetet med Brainlab och expansionen till den indiska marknaden. Försäljningen har ökat, och en lönsam avslutning på året förväntas. Framtida tillväxt stöds av nya produkter och partnerskap, s...
2/25/2025, 10:41 PM
by börsen84
1
Medicinteknikföretaget Nexstim publicerade sin delårsrapport för januari–september där de redogjorde för investeringar i lönsam tillväxt, utvecklingen av diagnostiksystemet NBS 6 samt utökningen av sitt kliniknätverk. Enligt företaget hade 11 nya system levererats och ytterligare...
10/31/2024, 11:28 AM
by börsen84
1
@antti.siltanen has done a good and high-quality analysis of this company. It’s worth reading! Inderes Nexstim: The end of the year laid a firmer foundation for the future - Inderes Revenue was slightly higher than the preliminary data suggested and the result hit our forecasts. ...
2/28/2024, 5:05 PM
by börsen84
1
Ägarna till Nexstim har en spännande dag på tisdag. Inderes Nexstim H2 on Tuesday: A record-breaking end to the year - Inderes The company issued a profit warning early in the year, saying that full-year EBITDA would be negative (guidance: Positive EBITDA). H2 revenue level of 4....
2/22/2024, 6:31 AM
by börsen84
1
Inderes Nexstim’s system sales progressed well in H2 - Inderes Nexstim’s H2 was positive in terms of announced system sales. During the reporting period, the company announced 16 system sales of which 11 occurred in Q4. The total number of deals will only be revealed in the H2 report...
1/13/2024, 11:31 PM
by börsen84
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.